Delving into the Latest Updates on Cisplatin/Glutathione with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Glutathione/cisplatin, Glutoxim

+ [1]

Target-

Mechanism

DNA alkylating agents

Therapeutic Areas

Neoplasms

Active Indication

Neoplasms

Inactive Indication

Breast CancerLeukemiaMyelodysplastic Syndromes+ [3]

Originator Organization

Cellectar Biosciences, Inc.

Active Organization

Sleep Number Labs

Inactive Organization

Cellectar Biosciences, Inc.

Drug Highest PhaseApproved

First Approval Date

RU (03 Jul 2001),

Neoplasms

Regulation-

Login to view timeline

Structure

Molecular FormulaCl2H6N2Pt

InChIKeyWCLAIRSNZFYZAT-UHFFFAOYSA-N

CAS Registry15663-27-1

View All Structures (2)

RATIONALE: Oxidized glutathione (NOV-002) may stimulate the immune system in different ways and stop tumor cells from growing. Drugs used in chemotherapy, such as doxorubicin, cyclophosphamide, and docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells. Giving NOV-002 together with chemotherapy before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed.
PURPOSE: This phase II trial is studying how well giving oxidized glutathione (NOV-002) together with doxorubicin and cyclophosphamide followed by docetaxel works in treating women with newly diagnosed stage II or stage III breast cancer.

Start Date04 Jun 2007

Sponsor / Collaborator

University of Miami

EUCTR2006-001990-32-IT / Not yet recruitingNot Applicable

A Randomized, Open-Label, Phase 3 Trial of NOV-002 in Combination withPaclitaxel and Carboplatin vs. Paclitaxel and Carboplatin Alone for theTreatment of Advanced Non-Small-Cell Lung Cancer (NSCLC) - ND

Start Date22 Nov 2006

Sponsor / Collaborator

Novelos Therapeutics, Inc.

NCT00347412 / CompletedPhase 3

Phase 3 Trial, Randomized, Open-Label, of NOV-002 in Combination With Paclitaxel and Carboplatin vs. Paclitaxel and Carboplatin Alone for the Treatment of Advanced Non-Small-Cell Lung Cancer (NSCLC)

The purpose of this clinical trial is to find out whether or not the combination of NOV-002 with chemotherapy (paclitaxel and carboplatin) is better at improving overall survival time when compared to chemotherapy alone in people with non-small cell lung cancer (NSCLC).
Earlier clinical trials in NSCLC showed that patients treated with NOV-002 in combination with chemotherapy had a better response (their tumors got smaller in one United States Phase 1/2 trial) than patients who received chemotherapy alone; and in two Phase 2 trials done in Russian patients, at the end of one year, patients treated with NOV-002 with chemotherapy had a better survival rate than patients who did not receive NOV-002 with their chemotherapy.

Start Date01 Nov 2006

Sponsor / Collaborator

Cellectar Biosciences, Inc.

100 Clinical Results associated with Cisplatin/Glutathione

Login to view more data

100 Translational Medicine associated with Cisplatin/Glutathione

Login to view more data

100 Patents (Medical) associated with Cisplatin/Glutathione

Login to view more data

59

Literatures (Medical) associated with Cisplatin/Glutathione

01 Jun 2022·Cell and Tissue Biology

Sigma-1 Receptor Ligands Chlorpromazine and Trifluoperazine Attenuate Ca2+ Responses in Rat Peritoneal Macrophages

Article

Author: Antonov, V G ; Milenina, L S ; Krutetskaya, Z I ; Krutetskaya, N I

Sigma-1 receptors are ubiquitous multifunctional ligand-regulated molecular chaperones in the endoplasmic reticulum membrane with a unique history, structure, and pharmacological profile. Sigma-1 receptors bind ligands of different chemical structure and pharmacological action and modulate a wide range of cellular processes in health and disease, including Ca²⁺ signaling. To elucidate the involvement of sigma-1 receptors in the processes of Ca²⁺ signaling in macrophages we studied the effect of sigma-1 receptor ligands, phenothiazine neuroleptics chlorpromazine and trifluoperazine, on Ca²⁺ responses induced by inhibitors of endoplasmic Ca²⁺-ATPases thapsigargin and cyclopiazonic acid, as well as by disulfide-containing immunomodulators Glutoxim and Molixan in rat peritoneal macrophages. Using Fura-2AM microfluorimetry we showed for the first time that chlorpromazine and trifluoperazine inhibit both phases of Ca²⁺ responses induced by Glutoxim, Molixan, thapsigargin, and cyclopiazonic acid in rat peritoneal macrophages. The data obtained indicate the participation of sigma-1 receptors in a complex signaling cascade caused by Glutoxim or Molixan and leading to an increase in intracellular Ca²⁺ concentration in macrophages. The results also indicate the involvement of sigma-1 receptors in the regulation of store-dependent Ca²⁺entry in macrophages.

01 Dec 2020·Bulletin of Experimental Biology and MedicineQ4 · MEDICINE

Human Diploid Fibroblast Cell Lines — a Model System for Studying Immunodulatory Properties of Modern Immunobiological Drugs and Viruses

Q4 · MEDICINE

Article

Author: Konyuschko, O I ; Kozhevnikova, T N ; Ishmuhametov, A A ; Ivanova, A L ; Ozherelkov, S V ; Sanin, A V ; Sotskova, S E ; Vorovich, M F

The immunomodulatory properties of immunobiological drugs Glutoxim and Phosprenyl we well as vesicular stomatitis virus and inactivated tick-borne encephalitis vaccine virus were studied using human diploid fibroblast cell line from the collection of M. P. Chumakov Federal Research Center for Research and Development of Immunobiological Products. All tested preparations exhibited immunomodulatory activity in human diploid fibroblast cell line. Glutoxim in doses of 0.1 and 0.25 μg/ml stimulated production of IL-6 and IL-10 during 24-48 h of culturing, but did not stimulate production of IL-1β. Phosprenyl, on the contrary, increased production of IL-1β and the levels of IL-6 and IL-10. Vesicular stomatitis virus stimulated the production of IL-1β, IL-6, and IL-10, while inactivated tick-borne encephalitis vaccine virus stimulated the production of cytokines IL-8 and IL-18. Immunomodulatory activity of inactivated tick-borne encephalitis vaccine virus was first demonstrated in the in vitro system.

01 Jan 2020·Doklady Biochemistry and BiophysicsQ4 · BIOLOGY

Neuroleptic Chlorpromazine Modulates Ca2+ Responses in Macrophages

Q4 · BIOLOGY

Article

Author: Nozdrachev, A D ; Krutetskaya, Z I ; Milenina, L S ; Antonov, V G

Using Fura-2AM microfluorimetry, we have shown for the first time that sigma-1 receptor antagonist neuroleptic chlorpromazine significantly inhibits glutoxim- and molixan-induced Ca²⁺ responses and Ca²⁺ responses induced by endoplasmic reticulum Са²⁺-ATPase inhibitors thapsigargin and cyclopiazonic acid in rat peritoneal macrophages. The results suggest the involvement of sigma-1 receptors in the signaling cascade induced by glutoxim or molixan and leading to intracellular Ca²⁺ concentration increase and in the regulation of store-dependent Ca²⁺ entry in macrophages.

100 Deals associated with Cisplatin/Glutathione

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
-	-	L01XY	DB05393

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Neoplasms	RU	Sleep Number Labs	03 Jul 2001

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Non-Small Cell Lung Cancer	Phase 1	CA	Cellectar Biosciences, Inc.	01 Nov 2006
Non-Small Cell Lung Cancer	Phase 1	IT	Cellectar Biosciences, Inc.	01 Nov 2006
Non-Small Cell Lung Cancer	Phase 1	US	Cellectar Biosciences, Inc.	01 Nov 2006
Non-Small Cell Lung Cancer	Phase 1	ES	Cellectar Biosciences, Inc.	01 Nov 2006
Non-Small Cell Lung Cancer	Phase 1	UA	Cellectar Biosciences, Inc.	01 Nov 2006
Non-Small Cell Lung Cancer	Phase 1	RU	Cellectar Biosciences, Inc.	01 Nov 2006
Non-Small Cell Lung Cancer	Phase 1	PL	Cellectar Biosciences, Inc.	01 Nov 2006
Non-Small Cell Lung Cancer	Phase 1	IL	Cellectar Biosciences, Inc.	01 Nov 2006
Non-Small Cell Lung Cancer	Preclinical	GB	Cellectar Biosciences, Inc.	01 Nov 2006
Non-Small Cell Lung Cancer	Preclinical	CH	Cellectar Biosciences, Inc.	01 Nov 2006

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT00345540 (CTgov)	Phase 2	Ovarian Cancer	15	Carboplatin+NOV-002	irmojrnlif(cmcanrednu) = ujbtsffseg moskczvqqz (oihqushwiv, ngwxbtkiuy - itvzjqphvi) View more	-	10 Mar 2015
WCLC2013	Not Applicable	Advanced Lung Non-Small Cell Squamous Carcinoma First line	172	Cixutumumab 20 mg/kg + Pemetrexed 500 mg/m2 + Cisplatin 75 mg/m2	(ttjinthjtj) = zgzxqljjin uloznkykuf (gkaizohzye ) View more	Negative	30 Oct 2013
WCLC2013	Not Applicable	Advanced Lung Non-Small Cell Squamous Carcinoma First line	172	Pemetrexed + Cisplatin	(ttjinthjtj) = qrgwmsfwni uloznkykuf (gkaizohzye ) View more	Negative	30 Oct 2013
NCT00499122 (CTgov)	Phase 2	Breast Cancer	41	CYCLOPHOSPHAMIDE+Doxorubicin+Docetaxel+NOV 002	lcpauctghy(eowgohciyq) = mzqnrosrkl evmbrmjjxv (tqdfqygbhv, lblprvxyly - ecpplnpbfw) View more	-	29 Mar 2013
NCT00499122 (Pubmed \| Breast Cancer Res)	Phase 2	HER2-negative breast cancer Neoadjuvant	41	NOV-002	(dnwnbegxyd) = umiddcouhp myrwyjclzs (cszpqkbnnu )	-	01 Feb 2012
ASCO2010	Phase 3	Non-Small Cell Lung Cancer	903	NOV-002 + paclitaxel + carboplatin	(jbuwqbdneo) = oaefeiozki pgdprhfzmt (lyfljtvits ) View more	Negative	20 Jun 2010
ASCO2010	Phase 3	Non-Small Cell Lung Cancer	903	paclitaxel + carboplatin	(jbuwqbdneo) = tdxhjwdygj pgdprhfzmt (lyfljtvits ) View more	Negative	20 Jun 2010
AACR2007	Phase 3	Nephrotoxicity	-	Cisplatin + NOV-002	tlvpcbjdif(cyfsekokpu) = vwnsivbdvm pszlwkfcrj (wbdtlbnizu ) View more	-	01 May 2007
ASCO2006	Phase 1/2	Non-Small Cell Lung Cancer First line	44	NOV-002 + carboplatin and paclitaxel (i.m.)	(zoeocwlyhh) = skyqbqgdzr apcqfhjbsg (eslfkcwfxw ) View more	Positive	20 Jun 2006
ASCO2006	Phase 1/2	Non-Small Cell Lung Cancer First line	44	NOV-002 + carboplatin and paclitaxel (s.c.)	(zoeocwlyhh) = toazezjbce apcqfhjbsg (eslfkcwfxw ) View more	Positive	20 Jun 2006